Live
- "Jathara" film success dedicated to the audience - Movie Team at the Thanks Meet
- Hamas denies its leaders leaving Qatar for Turkey
- Strategic Internal Audits in IT and Procurement Functions
- Pawan Kalyan addresses legislative council, emphasis on panchayat dumping yard management
- Muzarai dept to evict encroachments of temple lands
- CM Siddaramaiah inaugurates 27th Edition of Bengaluru Tech Summit
- India can and will play better, says Manolo Marquez after draw against Malaysia
- Top 4 Men’s Grooming Platforms Revolutionizing Self-Care in India
- 58% cut in NABARD funds from ₹5,600 cr to ₹2,340 cr for state
- YS Sunitha visits AP assembly, seeks update on probe in YS Viveka's murder case
Aurobindo gets FDA nod
Aurobindo Pharma Limited has received final approval from the US health regulator to manufacture and market generic version of heartburn relief medicine Famotidine tablets.
Hyderabad: Aurobindo Pharma Limited has received final approval from the US health regulator to manufacture and market generic version of heartburn relief medicine Famotidine tablets.
The approval by the US Food and Drug Administration (USFDA) is for strengths of 10 mg and 20 mg, the company said. This product is expected to be launched in the second quarter of 2016-17, it added.
The drug is bio-equivalent and therapeutically equivalent to the reference listed product Pepcid AC Tablets - 10 mg and 20 mg - of McNeil Consumer Pharmaceuticals Co, it said.
Citing IMS data, the company said that the approved product had an estimated market size of $31 million in the 12 month period ended February 2016.
Aurobindo Pharma also received final approval from the USFDA to manufacture and market pain relief drug Oxymorphone Hydrochloride tablets in the strengths of 5 mg and 10 mg.
"The approved ANDA is bio-equivalent and therapeutically equivalent to the reference listed drug product Opana (Oxymorphone Hydrochloride) tablets, 5 mg and 10 mg, of Endo Pharmaceuticals, Inc," it added.
Oxymorphone Hydrochloride tablets is used to help relieve moderate to severe acute pain where the use of an opioid is appropriate. The approved product has an estimated market size of $55.5 million for the twelve months ending February 2016 according to IMS.
